# PDIGREE (NCT03793166)

> Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

No report yet. It can be ordered.

- Drugs tested: cabozantinib plus nivolumab
- Indication: untreated metastatic clear cell renal cell carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03793166
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Clear Cell Renal Cell Carcinoma; Metastatic Malignant Neoplasm in the Bone; Metastatic Malignant Neoplasm in the Lymph Nodes; Metastatic Malignant Neoplasm in the Soft Tissue; Metastatic Malignant Neoplasm in the Viscera; Rhabdoid Tumor of the Kidney; Sarcomatoid Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8
- Interventions: Biospecimen Collection; Bone Scan; Cabozantinib; Computed Tomography; Ipilimumab; Magnetic Resonance Imaging; Nivolumab; Quality-of-Life Assessment; Questionnaire Administration
- Enrollment: 1175
- Primary outcome: Overall survival (OS)

## Some of the questions raised in the 20 most recent indexed sources

_Automated from the 20 newest of 21 indexed sources (May 2019 – Oct 2025). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- Whether adding cabozantinib to nivolumab after induction improves overall survival in patients without complete response or progression
- Whether early response after ipilimumab-nivolumab induction reliably guides the choice of subsequent treatment
- How the complete response rate with ipilimumab-nivolumab induction compares with earlier first-line ipilimumab-nivolumab data
- Whether cabozantinib is an effective next step after progression on ipilimumab-nivolumab induction

## Indexed commentary on PDIGREE so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 20 posts on X
- 1 post on Bluesky

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=pdigree-nct03793166

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03793166", "email": "<work email>"}; the inbox owner confirms by the emailed link.
